Brett T. Staahl

Brett T. Staahl is the co-founder and VP of Platform at Scribe Therapeutics. Previously, he was a Postdoctoral Fellow in the lab of Jennifer Doudna where he pioneered the use of CRISPR ribonucleoproteins, developed robust methods to deliver the proteins to various cell types both in vivo and ex vivo, and showed how they could safely and effectively be used to inactivate disease-causing genes and slow neurodegeneration. He has also worked at and consulted for other biotech startups. Brett has over 20 scientific publications in top-tier journals, several patents issued and pending, and received numerous research grants and awards including the F. Hoffmann-La Roche Postdoctoral Fellowship.

Prior to completing his postdoctoral work at the University of California, Berkeley, Brett received his B.S. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and his Ph.D. in Developmental Biology from Stanford University, where he studied the genetic circuitry underlying development of the mammalian nervous system and discovered de novo function-altering mutations in the genes of sporadic Amyotrophic Lateral Sclerosis (ALS) patients.